Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities

Lignende værker

• The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma
  af: Cui, Hongmei, et al.
  Udgivet: (2021)
• Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer
  af: Kashyap, Vivek K., et al.
  Udgivet: (2019)
• Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer
  af: Mahmud, Foyez, et al.
  Udgivet: (2020)
• An orally available tubulin inhibitor, VERU-111, suppresses triple-negative breast cancer tumor growth and metastasis and bypasses taxane resistance
  af: Deng, Shanshan, et al.
  Udgivet: (2019)
• Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy
  af: Banerjee, Souvik, et al.
  Udgivet: (2018)